J.P. Morgan analyst maintained a Buy rating on QuantumPharm, Inc. on July 23 and set a price target of HK$10.00. The company’s shares closed ye...
Currently, the analyst consensus on QuantumPharm, Inc. is a Moderate Buy with an average price target of HK$9.81.
Based on QuantumPharm, Inc.’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$280.78 million and a net profit of HK$40.27 million. In comparison, last year the company earned a revenue of HK$163.8 million and had a GAAP net loss of HK$279.59 million
In a report released on July 22, from HSBC maintained a Hold rating on QuantumPharm, Inc., with a price target of HK$8.00. The…
Morgan Stanley analyst maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H on May 28 and set a price target of…
J.P. Morgan analyst maintained a Buy rating on Tencent Holdings on May 14 and set a price target of HK$690.00. The company’s…
J.P. Morgan analyst maintained a Hold rating on Yankuang Energy Group Company Limited Class H on June 17 and set a price target…
In a report released yesterday, from J.P. Morgan maintained a Buy rating on XPeng, Inc. Class A, with a price target of…
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on AnaptysBio, with a price target of…
